FOL 005

Drug Profile

FOL 005

Alternative Names: FOL-005

Latest Information Update: 27 Jun 2016

Price : $50

At a glance

  • Originator Follicum AB
  • Class Proteins; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hair disorders

Most Recent Events

  • 20 Jun 2016 Follicum AB has patent protection for FOL 005 in USA (Follicum AB website, June 2016)
  • 10 Jun 2016 Preclinical trials in Hair disorders in Germany (Intradermal) before June 2016 (Follicum website, June 2016)
  • 21 Apr 2016 The Federal Institute for Drugs and Medical Devices (BfArM) and the Research Ethics Committee approve Clinical Trial application (phase IIa) for FOL 005 in Hair disorders (Follicum AB website, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top